Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial

Fineline Cube Dec 30, 2025
Company Drug

TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China

Fineline Cube Dec 30, 2025
Company Drug

CSPC Pharmaceutical’s PD-1 Monoclonal Antibody Enlangsubai Completes NMPA Market Approval Filing

Fineline Cube Mar 14, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the completion of a market approval...

Deals R&D

Pasteur Institute Suspends Joint Venture with Chinese Academy of Sciences

Fineline Cube Mar 14, 2023

France’s Pasteur Institute has announced its decision to suspend its joint-venture (JV) partnership with the...

Company Medical Device

Boston Scientific Launches REPLACE Study for FARAPULSE PFA System in China

Fineline Cube Mar 14, 2023

US-based medical technology major Boston Scientific Corporation (NYSE: BSX) has announced the initiation of the...

Company Drug

Chipscreen’s Epidaza Receives TFDA Approval for Breast Cancer Treatment in Taiwan

Fineline Cube Mar 13, 2023

Shenzhen Chipscreen Pharmaceutical Co., Ltd’s partner, GNT Biotech & Medicals Corporation, has announced that it...

Company Deals

Silicon Valley Bank Collapse Impacts Tech and Biotech Sectors Globally

Fineline Cube Mar 13, 2023

The tech and biotech sectors are grappling with the implications of the collapse of US-based...

Company Deals

Allorion Therapeutics Raises USD 50 Million in Series B Financing to Advance Drug Development

Fineline Cube Mar 13, 2023

Allorion Therapeutics, a next-generation precision medicine small molecule drug developer based in Guangzhou, reportedly raised...

Company Deals

XtalPi and Chia Tai Tianqing Achieve Phase II Milestone in Cancer Drug Development

Fineline Cube Mar 13, 2023

Sino-US artificial intelligence (AI) firm XtalPi Inc. has partnered with China’s Chia Tai Tianqing to...

Company Deals

Overland Pharmaceuticals Partners with GoBroad Healthcare to Strengthen Cell Therapy Research

Fineline Cube Mar 13, 2023

China-based firm Overland Pharmaceuticals has entered into a strategic partnership with GoBroad Healthcare Group to...

Company Drug

Haihe Pharmaceutical Initiates Global Phase I Clinical Study for BET-BD2 Inhibitor HH3806

Fineline Cube Mar 13, 2023

Shanghai Haihe Pharmaceutical Co., Ltd has announced the first patient dosing of a global multi-center...

Company Drug

CanSino Biologics Initiates Phase Ib Study for Innovative Protein-Based Pneumococcal Vaccine

Fineline Cube Mar 13, 2023

China-based vaccines specialist CanSino Biologics Inc. has announced the initiation and first subject enrollment of...

Company Deals

Zenshine Pharmaceuticals Raises RMB 100 Million in Series B Financing for Drug Development

Fineline Cube Mar 13, 2023

China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd reportedly raised over RMB 100...

Company Deals

Livzon Pharmaceutical Secures Exclusive Rights to Onconic’s GERD Treatment Zastaprazan

Fineline Cube Mar 13, 2023

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced a licensing agreement with South Korean...

Company Drug

CStone’s Ayvakit Shows Significant Improvements in ISM at AAAAI Meeting

Fineline Cube Mar 13, 2023

China-based CStone Pharmaceuticals (HKG: 2616) announced that its US partner, Blueprint Medicines, published detailed data...

Company Medical Device

Lifetech’s IBS Angel Stent System Gains EU CE MDR Certification

Fineline Cube Mar 10, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received CE MDR certification...

Company Deals

Olipharma Secures Funding for Manufacturing Expansion in Pre-Series A+ Round

Fineline Cube Mar 10, 2023

Olipharma, a Contract Development and Manufacturing Organization (CDMO) specializing in small nucleic acid drugs and...

Company Drug

Inventiva and Chia Tai Tianqing’s Lanifibranor Advances with CDE Filing

Fineline Cube Mar 10, 2023

France-based Inventiva S.A. and China’s Chia Tai Tianqing have successfully filed a clinical trial application...

Company Drug

Simcere’s SIM0237 Begins Clinical Study for PD-L1 and IL-15 Targeting Bispecific Antibody

Fineline Cube Mar 10, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...

Deals Drug

AusperBio and Asymchem Form Strategic Partnership for Drug Development

Fineline Cube Mar 10, 2023

China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership...

Policy / Regulatory

NHSA’s 2022 Healthcare Security Bulletin Reveals Break-Even Performance

Fineline Cube Mar 10, 2023

The National Healthcare Security Administration (NHSA) has released its annual “Healthcare Security Development Statistical Bulletin”...

Company Drug

Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008

Fineline Cube Mar 10, 2023

China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...

Posts pagination

1 … 488 489 490 … 602

Recent updates

  • Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
  • Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial
  • TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China
  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Company Drug

Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial

Company Drug

TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.